The company has received approval from India''s drug regulator DCGI to manufacture and market the tablets, Bajaj Healthcare said in a BSE filing.
"We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure and offer patients much-needed and timely therapy options," Bajaj Healthcare Joint MD Anil Jain said.
The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team, Bajaj Healthcare said.
Shares of Bajaj Healthcare closed at Rs 583.05 per scrip on BSE, up steep 10.85 percent from its previous close. PTI AKT SHW SHW
Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI